TPP allies with Sprint Bioscience to develop cancer drugs

11/1/2012 | Pharmaceutical Business Review Online

Sprint Bioscience and TPP Global Development agreed to collaborate in the development of small molecule choline kinase inhibitors for treatment of cancer. "Choline kinase is an exciting metabolic target and fits well within the rest of TPP's cancer metabolism portfolio," TPP CEO Tom Brown said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC